

# Gastrointestinal microbiome, what is behind faecal microbiota transplantation?

P. Thomson<sup>1</sup>, P. Núñez<sup>2,3</sup>, R. Quera<sup>3</sup> and C. Bay<sup>4</sup>

1) Veterinarian School of Medicine, Faculty of Life Science, Andrés Bello University, Avenida República 440, 2) Department of Gastroenterology, Hospital San Juan De Dios – University of Chile, Huérfanos 3255, Santiago, 3) Gastroenterology Department, Clínica Universidad de los Andes, Avda. Plaza 2501 and 4) Department of Pediatrics, Medicine School, Pontificia Universidad Católica de Chile, Marcoleta 367, Santiago, Chile

## Abstract

The intestinal microbiota is made up of billions of microorganisms that coexist in an organised ecosystem, where strict and facultative anaerobic bacteria predominate. The alteration or imbalance of these microorganisms, known as dysbiosis, can be associated with both gastrointestinal and extraintestinal diseases.

Based on a review of the literature, the intestinal microbiota is described in its state of health, the changes associated with some gastrointestinal diseases and the potential role that faecal microbiota transplantation has in the reestablishment of an altered ecosystem. Undoubtedly, the information revealed makes us reflect on the indication of faecal microbiota transplantation in various pathologies of intestinal origin. However, to ensure the efficacy and safety of this therapy, more studies are needed to obtain more evidence.

© 2021 The Authors. Published by Elsevier Ltd.

**Keywords:** Dysbiosis, faecal microbiota transplantation, gastrointestinal illness, microbiome

**Original Submission:** 12 March 2021; **Revised Submission:** 6 May 2021; **Accepted:** 9 May 2021

**Article published online:** 13 May 2021

**Corresponding author:** P. Thomson, Avenida República 440, Santiago, CP 8370251, Chile. Tel.: +56 9 67071581.

**E-mails:** [pamela.thomson@unab.cl](mailto:pamela.thomson@unab.cl) (P. Thomson), [pnunez@clinicauandes.cl](mailto:pnunez@clinicauandes.cl) (P. Núñez), [rquera@clinicauandes.cl](mailto:rquera@clinicauandes.cl) (R. Quera), [constanzabaym@gmail.com](mailto:constanzabaym@gmail.com) (C. Bay)

## Introduction

The gut microbiota is made up of more than 100 trillion different microorganisms, including bacteria, fungi, viruses and protozoa [1]. It is a complex ecosystem that varies in number, depending on the identification tools used; therefore, both metagenomics and culturomics approaches are required to better understand the diversity and richness of bacteria present in the human gut microbiota [2]. In healthy individuals, it is dominated by strict anaerobes, 87% corresponding to the bacterial phyla *Bacteroidetes* and *Firmicutes*. To a lesser extent, bacteria belonging to other

phyla such as *Actinobacteria*, *Proteobacteria* and *Verrucomicrobia* can be found [3,4].

The proportion of bacteria varies throughout the gastrointestinal tract. The colon contains the highest number and diversity of species, compared with the stomach and small intestine [3].

One of the main roles of the gut microbiota is to contribute to the fermentation of various types of indigestible fibres by the small intestine. This activity results in the release of short-chain fatty acids (SCFAs), acetate, propionate and butyrate, which are used as an energy source by the colonic epithelium [5,6]. These molecules are essential for intestinal integrity, regulating luminal pH and mucus production [7,8]. In addition, they directly impact the development and activity of the immune system. They regulate various inflammatory processes, considering that the intestinal epithelium represents a stable barrier between lymphoid tissue and the microbiome itself [9,10].

It has been observed that losses of microbiota homeostasis or dysbiosis are associated with some diseases, which are explained by the imbalance and loss some species, such as *Faecalobacterium prausnitzii*, considered one intestinal health

biomarker [11,12] (Fig. 1). Studies have shown that this dysbiosis is involved in the development of a wide range of diseases, both intestinal and extraintestinal [13].

However, it is not fully understood whether these changes in the microbiota the cause of the disease or of it a consequence are, except for *Clostridioides difficile* infection where there is a clear causality [14]. Faecal microbiota transplantation (FMT) represents a unique procedure, aimed at restoring the natural diversity of the gastrointestinal microbiota and preventing the recurrence of a nosocomial disease, by correcting these imbalances with a healthy external microbiota [15].

The objective of this review was to describe the normal intestinal microbiota and the changes that occur in different gastrointestinal pathologies, to understand the basis of FMT as a therapy (going beyond *Clostridioides difficile*). A systematised search was carried out in Embase, Web of Science and PubMed.

## Gut microbiota in gastrointestinal diseases

### Inflammatory bowel disease (IBD)

IBD mainly encompasses Crohn's disease (CD) and ulcerative colitis, both of chronic course characterised by alternating periods of relapse and remission. Their clinical symptoms that include abdominal pain, diarrhoea, fatigue and extraintestinal manifestations that significantly affect patients' quality of life [16,17].

The aetiology of this disease is known as multifactorial, where there is interaction between the microbiome, genetic, environmental and immunological factors [18,19]. To respect,

studies have shown that an alteration in the composition and function of the microbiome [20].

Characteristic findings in IBD include a significant decrease in bacterias of the phyla *Firmicutes* and *Bacteroidetes*, including species such as *Clostridium symbiosum* and *Bacteroides dorei*. These bacteria are SCFA producers, such as butyrate, propionate and acetate [14,21]. The latter deliver energy to cells of the colonic epithelium but can also induce the differentiation of regulatory T cells of the immune response [22]. Furthermore, Brown et al. add that the sphingolipids produced by *Bacteroides* also play an important role in maintaining homeostasis, reducing inflammation of the intestine [23]. Other studies point out that both the transfer of proinflammatory bacteria and the transplantation of microbiota from sick to healthy mice can induce inflammation [24]. Based on these findings, FMT has been evaluated as a possible therapy for IBD through the restoration of the microbiome. It has demonstrated a clinical response in 53.8%, with a clinical and endoscopic remission in 37% [25]. Recently a meta-analysis that included 28 articles containing 976 IBD patients showed that responses and remission rated were more favourable for patients receiving repeated FMT regimens and antibiotic pretreatment strategies. However, the heterogeneity for all pooled analyses was high. Fifteen of the 18 studies (83%) that evaluated for shifts in specific gut microbial taxa reported increases in the abundance of anaerobes purported to produce health promoting anti-inflammatory SCFAs, such as *Bifidobacterium*, *Roseburia*, *Lachnospiraceae*, *Prevotella*, *Ruminococcus* and *Clostridioides* related species. Overall, FMT in patients with IBD was shown to be safe and well tolerated [26]. Others have also




FIG. 1. Human microbiomes in gastrointestinal diseases.

confirmed that FMT could be an effective and safe therapy for CD. Interestingly, subanalyses suggested the rate of clinical remission with fresh stool FMT was higher than with frozen stool FMT (73% vs 43%;  $p < 0.05$ ) [27]. A systematic review that included nine studies containing 69 patients with chronic pouchitis showed that FMT has promising results and could be a useful and secure strategy in this scenario [28]. However, more studies are still needed to provide categorical evidence. Thus, the Third European consensus on Ulcerative Colitis of the European Crohn's and Colitis Organization highlights the need for additional studies to identify the best strategy, considering the route of administration, type of donor and security profile [29].

### Irritable bowel syndrome

Irritable bowel syndrome is a functional gastrointestinal disorder with symptoms including abdominal pain associated with a change in the shape or frequency of stool and colonic distention. The pathophysiology is not fully understood, but an altered connection between the gut and the brain is well established, leading to motility disturbances, visceral hypersensitivity [30].

The intestinal bacterial profile in patients with irritable bowel syndrome (IBS) differs from that in healthy subjects. The intestine of IBS patients has a lower abundance of butyrate-producing bacteria (*Erysipelotrichaceae* and *Ruminococcaceae* spp.) and a higher abundance of methane-producing bacteria (*Methanobacteriales* spp.) [31]. Also, the production of bile acids (BAs) has been investigated due to its ability to modulate intestinal function and its close connection with the intestinal microbiome and its relationship with irritable bowel syndrome. The study establishes an association between the presence of diarrhoea and visceral hypersensitivity and alteration of the metabolism of BAs in the intestine of patients with IBS, attributing this to an intestinal dysbiosis with a special reduction in genera of the *Ruminococcaceae* family [32], known for its high production of SCFAs [33].

A study carried out from the faeces of individuals with this syndrome identified lower levels of *Lactobacillus*, *Bifidobacterium*, *Eubacterium rectale* and *Faecalibacterium prausnitzii* [34], all of which are SCFA producers. Particularly, *F. prausnitzii* is one of the major producers of butyrate, which is why it is considered an indicator or biomarker of intestinal health [12,13]. On the contrary, low levels of these microorganisms could be predictive of CD [35].

Clearly, there are differences between the microbiota of IBS patients and the one of healthy patients. Despite this background, a single bacterial species has not been identified as a causative agent. Several authors agree that patients with IBS have an increase in microorganisms with proinflammatory properties, like some belonging to the *Veillonellaceae*,

*Pasteurellaceae* and *Fusobacteriaceae* families. Species such as enteroinvasive and adherent *Escherichia coli* and *Ruminococcus gnavus* have also been identified [36,37].

Other authors have also reported a decrease in the *Clostridiales-Prevotella* enterotype in individuals with IBS [38]. Undoubtedly, one of the strongest links between IBS and the intestinal microbiota is pointed out by a report in which FMT was performed. Faeces from IBS patients was transferred to healthy mice, which was associated with IBS phenotype characteristics, such as intestinal dysmotility, increased intestinal permeability and visceral hypersensitivity [39].

El-Salhy et al. analysed the potential role of FMT in patients with IBS and their results showed that this therapeutic strategy would be an effective treatment in this scenario. The response to FMT increased with the dose (76.9% and 89.1% of the patients who received 30 g FMT and 60 g FMT, respectively). The intestinal bacterial profiles changed also significantly in the groups received FMT (higher signals for *Eubacterium bifforme*, *Lactobacillus* spp. and *Alistipes* spp. after transplantation, and lower signals for *Bacteroides* spp.). The FMT adverse events were mild self-limiting gastrointestinal symptoms [40]. FMT increases the faecal SCFA and butyric levels in IBS patients. The increase in the butyric acid level was inversely correlated with abdominal symptoms and fatigue in IBS patients following FMT. These results suggest that SCFAs and the butyric acid play a role in the pathophysiology of IBS [41]. However, a systematic review and metaanalysis that included 4 studies showed not an overall clinical benefit from FMT for IBS patients. A discrepancy in efficacy of FMT for IBS may be related to the differences in route of administration, placebo treatment, FMT frequency and IBS subtype included among the studies [42].

### Steatosis/non-alcoholic fatty liver disease

In recent years, a direct relationship between obesity and metabolic disorders related to changes in the intestinal microbiota has been described [43,44]. In general, obese people have a higher concentration of bacteria of the phylum *Firmicutes* and less *Bacteroidetes*. Other studies have reported a decrease in *Bifidobacterium* concentrations in overweight subjects [45]. Metabolic syndrome, which includes insulin resistance, dyslipidemia, high blood pressure and increased abdominal circumference, is strongly associated with long-term development of type 2 diabetes and cardiovascular disease. The hepatic manifestation of this syndrome, although not part of its criteria, is non-alcoholic fatty liver disease. In this regard, metagenomic studies in humans have identified specific changes in the gut microbiota [46], including an increase in bacteria that contribute to insulin resistance, such as *Prevotella copri* and *Bacteroides vulgatus* [47]. Another study in obese mice, to which metformin was administered, described an increase in

*Akkermansia muciphila*, which has been associated to glucose homeostasis [48,49].

Likewise, it has been described that signalling molecules produced by intestinal bacteria can affect the intestinal integrity, the sensation of satiety and the metabolic phenotype of the host. SCFAs are the best-studied example; in this regard, butyrate exerts a positive regulation of tight-junction proteins such as claudin-1, induces apoptosis of T cells to eliminate the source of inflammation [50], while suppressing inflammation mediated by IFN- $\gamma$  in colon epithelial cells [51] and induces intestinal gluconeogenesis by different pathways [52]. For its part, acetate generates an increase in plasma incretin hormones, reduces TNF $\alpha$  and indirectly generates changes in the metabolism of lipids and glucose [53]. Bile acids are another class of molecules that play a role in microbiome-host communication, mediated by the nuclear farnesoid X receptor, which has been related to the regulation of glucose in obese mice [54].

### Liver cirrhosis and its complications

Changes in the gut microbiome play a role in the progression of cirrhosis and its complications. On the one hand, inflammatory mediators, endotoxemia and haemodynamic alterations lead to complications such as spontaneous bacterial peritonitis and hepatic encephalopathy (HE) [55]. The latter is the most studied in relation to the gut-brain axis [56]. Hepatic encephalopathy begins with cognitive changes or psychomotor deficits that can only be detected with psychometric or neurophysiological tests. This entity called minimal HE already presents alterations in the intestinal microbiota. Thus, Zhang et al. observed an increase in urease-producing bacteria such as *Streptococcus salivarius* in cirrhotic patients. This finding was significantly higher in patients with minimal HE than in those without HE ( $p = 0.03$ ) and was associated with a greater accumulation of ammonia in those with HE ( $R = 0.58$ ,  $p = 0.003$ ) than in the other group [57].

In turn, a change in the microbiota has been observed depending on the stage of progression of cirrhosis. There are two scoring systems, the Child-Turcotte-Pugh (includes albumin, bilirubin, prothrombin time, degree of encephalopathy and ascites) and MELD Model for end-stage liver disease (logarithmic score that includes bilirubin, creatinine and INR of prothrombin time). The higher the score, the worse the prognosis. Thus, a higher Child score has been associated with an increase of *Streptococcaceae*, *Veillonellaceae* and *Enterobacteriaceae* bacterial families, and a decrease in *Lachnospiraceae* [58]. Another study reported a higher MELD was associated with a microbiota with a higher number of *Enterobacteriaceae* and a lower proportion of *Lachnospiraceae* and *Ruminococcaceae* [59].

Current evidence, despite being scarce, points towards FMT could be an effective, safe and tolerable strategy in some liver

diseases. However, some unanswered questions remain about the optimal dose, the administration route, the long-term effects and the selection of the optimal donor. The gut microbiota appears to play a critical role in age-related immune clearance of hepatitis B virus [60]. An open-label pilot trial of FMT for chronic hepatitis B patients showed that this therapeutic strategy could induce HBeAg clearance in patients who have persistent positive HBeAg even after long-term antiviral treatment [61]. Given the current evidence of the paramount role of intestinal microbiota in HE and the limited therapeutic options, some studies have evaluated the efficacy and safety of FMT in this scenario [62]. An open-label randomised clinical trial included 20 cirrhotic patients with recurrent HE who were randomised 1:1 into FMT following 5 days of antibiotic pretreatment or standard of care. The study showed that FMT was safe, tolerated and effective with lower hospitalisations and improved cognitive tests. A relative increase in *Lachnospiraceae* and *Ruminococcaceae* was observed in the FMT arm compared with the SOC arm [63]. The same group, in a randomised and placebo-controlled trial (phase I), showed that encapsulated FMT did not reduce the rate of HE episodes compared with standard of care, despite improved cognitive functioning and increased duodenal microbial diversity [64]. Nevertheless, this study has some limitations that limited the conclusions about the efficacy of the oral route for FMT: the small sample size included in the study (20 patients), rifaximin and was not proton-pump inhibitors discontinued, scenarios that can modify intestinal microbiota.

### Primary sclerosing cholangitis

BAs, which participate in the emulsification and absorption of fats from the diet, are actively reabsorbed in the terminal ileum in a percentage close to 95%. The rest is unconjugated and transformed by the colonic microbiota, then passively passing to the portal circulation. BAs play a role in the control of bacterial overgrowth by binding to FXR (Farnesoid X receptor), which allows the production of antimicrobial peptides [24]. In primary sclerosing cholangitis (PSC), secondary to cholestasis there is an alteration of these BAs, leading to an alteration of the microbiota [65,66]. There is a decrease in the abundance and diversity of bacterial species [67,68]. Some subtypes such as *Veillonella* genus has been described up to 4.8 times more frequent in individuals with PSC versus healthy individuals and 7.8 times compared to ulcerative colitis, so this change is thought to be related to a liver disease rather than IBD [69].

### Necrotising enterocolitis

Necrotising enterocolitis (NEC) is a life-catastrophic disease almost exclusively affecting in preterm infants. NEC has a mortality rate as high as 20-30% [70]. The aetiology of NEC is

multifactorial with prematurity, low birth weight, administration of enteral feeds and antibiotic exposure associated with development of the disease. The inflammation of the intestine leading to bacterial invasion causing cellular damage and death which causes necrosis of the colon and intestine [62,71]. Compared with term infants, the intestinal microbiota of preterm infants has fewer bacterial species, less diversity, smaller proportions of beneficial bacteria including *Lactobacillus* and *Bifidobacterium* species and increased levels of bacteria that can become pathogenic Gammaproteobacteria (i.e. *E. coli*, *Klebsiella pneumoniae*) [72,73]. Since then, numerous trials evaluating the efficacy of probiotics in preventing NEC have been conducted, with some demonstrating efficacy [66,74]. Oral administration of *Lactobacillus* and *Bifidobacterium* was shown to prevent NEC in preterm infants [75], and when administered in combination with breast milk, there was significant reduction in the incidence of NEC compared with infants receiving breast milk alone [76].

## Conclusion

At present, FMT is recommended in patients with recurrent disease caused by *Clostridioides difficile*. However, owing to the association that exists between the alteration of some species of the intestinal microbiota and the presentation of pathologies such as IBD, IBS, steatosis/non-alcoholic fatty liver disease, PSC and others, a few studies carried out in animal models and others in humans, have shown that this procedure could be used as a therapeutic alternative in other intestinal diseases.

Some bacterial species present in the gut microbiota have been identified as healthy biomarkers, being associated with a high production of SCFAs. Butyrate is an energy source of the colonic epithelium and can modulate various inflammatory processes that directly impact the development and activity of the immune system.

These findings give continuity to the idea of using faecal transplantation in other pathologies. Further research in this area is needed to consider this therapy as effective and safe in human patients.

## Author contributions

P Thomson made substantial contributions in conception and design of the work, interpretation of data, revising the work critically and approved the final version of the review. R Quera made substantial contributions in the review conception, revising it critically and approved the final version. P Nuñez made the conception of the work, with the analysis and

interpretation of data works, drafted and revised it critically and approved the final version and finally C Bay drafting the work and final approval of the version to be published.

## Transparency declaration

No conflict of interest.

## Acknowledgements

The authors thank ANID PAI Project #77190079.

## References

- [1] Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. *Clin J Gastroenterol* 2018;11:1–10.
- [2] Lagier JC, Khelaifia S, Alou MT, Ndongo S, Dione N, Hugon P, Caputo A, Cadoret F, Traore SI, Seck EH, Dubourg G, Durand G, Mourembou G, Guilhot E, Togo A, Bellali S, Bachar D, Cassir N, Bittar F, Delerce J, Mailhe M, Ricaboni D, Bilen M, Dangui Nieko NP, Dia Badiane NM, Valles C, Mouelhi D, Diop K, Million M, Musso D, Abrahão J, Azhar EI, Bibi F, Yasir M, Diallo A, Sokhna C, Djossou F, Vitton V, Robert C, Rolain JM, La Scola B, Fournier PE, Levasseur A, Raoult D. Culture of previously uncultured members of the human gut microbiota by culturomics. *Nat Microbiol* 2016 Nov 7;1:16203. <https://doi.org/10.1038/nmicrobiol.2016.203>. PMID: 27819657.
- [3] Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada TA. Human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 2010;464:59–65.
- [4] Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. *World J Gastroenterol* 2015;21:8787–803.
- [5] Wong JM, de Souza R, Kendall CVW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. *J Clin Gastroenterol* 2006;40:235–43.
- [6] Cerqueira FM, Photenhauer AL, Pollet RM, Brown HA, Koropatkin NM. Starch digestion by gut bacteria: crowdsourcing for carbs. *Trends Microbiol* 2020;28(2):95–108. <https://doi.org/10.1016/j.tim.2019.09.004>.
- [7] Thomson P, Medina DA, Ortúzar V, Gotteland M, Garrido D. Anti-inflammatory effect of microbial consortia during the utilization of dietary polysaccharides. *Food Res Int* 2018;109:14–23. <https://doi.org/10.1016/j.foodres.2018.04.008>.
- [8] Chen D, Jin D, Huang S, Wu J, Xu M, et al. Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota. *Cancer Lett* 2020;469:456–67. <https://doi.org/10.1016/j.canlet.2019.11.019>.
- [9] Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. *Nature* 2016;6:65–74.
- [10] Tamburini S, Shen N, Wu HC, Clemente JC. The microbiome in early life: implications for health outcomes. *Nat Med* 2016;22:713–6.
- [11] Ferreira-Halder CV, Faria AVS, Andrade SS. Action and function of *Faecalibacterium prausnitzii* in health and disease. *Best Pract Res Clin Gastroenterol* 2017;31(6):643–8. <https://doi.org/10.1016/j.bpg.2017.09.011>.
- [12] Caenepeel C, Sadat Seyed Tabib N, Vieira-Silva S, Vermeire S. Review article: how the intestinal microbiota may reflect disease activity and

- influence therapeutic outcome in inflammatory bowel disease. *Aliment Pharmacol Ther* 2020 Sep 24. <https://doi.org/10.1111/apt.16096>. Epub ahead of print. PMID: 32969507.
- [13] Cani P. Gut microbiota – at the intersection of everything? *Nat Rev Gastroenterol Hepatol* 2017;14:321–2. <https://doi.org/10.1038/nrgastro.2017.54>.
- [14] Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent *Clostridium difficile* infection. *Clin Infect Dis* 2011;53:994–1002.
- [15] Wortelboer K, Niewdorp M, Herrema H. Fecal microbiota transplantation beyond *Clostridioides difficile* infections. *EBioMedicine* 2019;44:716–29.
- [16] Kim YS, Jung S-A, Lee K-M, et al. Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases. *Intestinal Res* 2017;15(3):338–44.
- [17] Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. *J Gastroenterol* 2018;53:305.
- [18] de Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of etiology, pathogenesis, and therapy. *Nat Rev Gastroenterol Hepatol* 2017 Dec;14(12):739–49.
- [19] Clooney AG, Eckenberger J, Laserna-Mendieta E, Sexton KA, Bernstein MT, Vagianos K, Sargent M, Ryan FJ, Moran C, Sheehan D, Sleator RD, Targownik LE, Bernstein CN, Shanahan F, Claesson MJ. Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study. *Gut* 2021;70(3):499–510.
- [20] Al Bander Z, Nitert MD, Mousa A, Naderpoor N. The gut microbiota and inflammation: an overview. *Int J Environ Res Public Health* 2020;17(20):7618.
- [21] Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. *J Allergy Clin Immunol* 2020;145(1):16–27. <https://doi.org/10.1016/j.jaci.2019.11.003>.
- [22] Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Kato T, Takahashi M, Fukuda NN, Murakami S, Miyachi E, Hino S, Atarashi K, Onawa S, Fujimura Y, Lockett T, Clarke JM, Topping DL, Tomita M, Hori S, Ohara O, Morita T, Koseki H, Kikuchi J, Honda K, Hase K, Ohno H. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature* 2013;504:446–50.
- [23] Brown EM, Ke X, Hitchcock D, et al. Bacteroides-Derived sphingolipids are critical for maintaining intestinal homeostasis and symbiosis. *Cell Host Microbe* 2019;25(5):668–80. <https://doi.org/10.1016/j.chom.2019.04.002>. e7.
- [24] Reinoso Webb C, den Bakker H, Koboziev I, Jones-Hall Y, Rao Kottapalli K, Ostanin D, et al. Differential susceptibility to T cell-induced colitis in mice: role of the intestinal microbiota. *Inflamm Bowel Dis* 2018;24:361–79.
- [25] Caldeira LdF, Borba HH, Tonin FS, Wiens A, Fernandez-Llimos F, Pontarolo R. Fecal microbiota transplantation in inflammatory bowel disease patients: a systematic review and meta-analysis. *PLoS ONE* 2020;15(9):e0238910. <https://doi.org/10.1371/journal.pone.0238910>.
- [26] Mocanu V, Rajauraban S, Dang J, Kung JY, Deehan EC, Madsen KL. Repeated fecal microbial transplantations and antibiotic pre-treatment are lined to improved clinical response and remission in Inflammatory Bowel Disease: a systematic review and pooled proportion meta-analysis. *J Clin Med* 2021;10:959.
- [27] Cheng F, Huang Z, Wei W, Li. Fecal microbiota transplantation for Crohn's disease: a systematic and meta-analysis. *Tech Coloproctol* 2021 Mar 23.
- [28] Cold F, Kousgaard SB, Halkjaer S, Petersen AM, Nielsen HL, Thorlacius-Ussing O, et al. Fecal microbiota transplantation in treatment of Chronic Pouchitis: a systematic review. *Microorganisms* 2020;8:1433.
- [29] Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, et al. Third European evidence based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. *J Crohns Colitis* 2017;11:769–84. <https://doi.org/10.1093/ecco-icc/jjx009>.
- [30] Andrews CN, Sidani S, Marshall JK. Clinical management of the microbiome in irritable bowel syndrome. *J Can Assoc Gastroenterol* 2020 Jan 4;4(1):36–43.
- [31] El-Salhy M, Hatlebakk JG, Hausken T. Diet in irritable bowel syndrome (IBS): interaction with gut microbiota and gut hormones. *Nutrients* 2019;11(8):1824.
- [32] Wei W, Wang HF, Zhang Y, Zhang YL, Niu BY, Yao SK. Altered metabolism of bile acids correlates with clinical parameters and the gut microbiota in patients with diarrhea-predominant irritable bowel syndrome. *World J Gastroenterol* 2020 7;26(45):7153–72.
- [33] Smirnova E, Puri P, Muthiah MD, Daitya K, Brown R, Chalasani N, Liangpunsakul S, Shah VH, Gelow K, Siddiqui MS, Boyett S, Mirshahi F, Sikaroodi M, Gillevet P, Sanyal AJ. Fecal microbiome distinguishes alcohol consumption from alcoholic hepatitis but does not discriminate disease severity. *Hepatology* 2020 Jul;72(1):271–86.
- [34] Liu HN, Wu H, Chen YZ, Chen YJ, Shen XZ, Liu TT. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: a systematic review and meta-analysis. *Dig Liver Dis* 2017;49:331–7. 38.
- [35] Miquel S, Martín R, Rossi O, Bermúdez-Humarán LG, Chatel JM, Sokol H, Thomas M, Wells JM, Langella P. Faecalibacterium prausnitzii and human intestinal health. *Curr Opin Microbiol* 2013 Jun;16(3):255–61. <https://doi.org/10.1016/j.mib.2013.06.003>. Epub 2013 Jul 3. PMID: 23831042.
- [36] Sokol H, Lepage P, Seksik P, Dore J, Marteau P. Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active *Escherichia coli* in the microbiota of patients with ulcerative colitis. *J Clin Microbiol* 2006;44:3172–7.
- [37] Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. *Gut* 2011;60:631–7.
- [38] Tap J, Derrien M, Tornblom H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. *Gastroenterology* 2017;152:111–23. e8.39.
- [39] Crouzet L, Gaultier E, Del'Homme C, et al. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. *Neurogastroenterol Motil* 2013;25:e272–82.
- [40] El-Salhy M, Hatlebakk JG, Gilja OH, Bråthen Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomized, double-blind, placebo-controlled study. *Gut* 2020;69(5):859–67.
- [41] El-Salhy M, Valeur J, Hausken T, Hatlebakk Gunnar. Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome. *J Neurogastroenterol Motil* 2021;33:e13983.
- [42] Xu D, Chen VL, Steiner CA, Berinstein JA, Eswaran S, Waljee AK, Higgins PDR, Owyang C. Efficacy of fecal microbiota transplantation in Irritable Bowel Syndrome: a systematic review and meta-analysis. *Am J Gastroenterol* 2019;114:1043–50.
- [43] Roberts A. The safety and regulatory process for low calorie sweeteners in the United States. *Physiol Behav* 2016;164(Pt B):439–44. <https://doi.org/10.1016/j.physbeh.2016.02.039>.
- [44] Peng-Xu W, Xin-Ru D, Chen-Hong Z, Hui-Juan Y. Gut microbiota and metabolic syndrome. *Chin Med J* 2020 Apr 5;133(7):808–16.
- [45] Wu S, Tao N, German JB, Grimm R, Lebrilla CB. Development of an annotated library of neutral human milk oligosaccharides. *J Proteome Res* 2010;9:4138–51.
- [46] Remely M, Hippe B, Zanner J, Aumueller E, Brath H, Haslberger AG. Gut microbiota of obese, type 2 diabetic individuals is enriched in *Faecalibacterium prausnitzii*, *Akkermansia muciniphila* and *peptostreptococcus anaerobius* after weight loss. *Endocr Metab Immune Disord Drug Targets* 2016;16(2):99–106. <https://doi.org/10.2174/1871530316666160831093813>.

- [47] Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyötylainen T, Nielsen T, Jensen BAH, Forslund K, Hildebrand F, Prifti E, Falony G, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. *Nature* 2016;535:376–81.
- [48] Shin N-R, Lee J-C, Lee H-Y, Kim M-S, Whon TW, Lee M-S, Bae J-W. An increase in the *Akkermansia* spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. *Gut* 2014;63:727–35.
- [49] Li J, Lin S, Vanhoutte PM, Woo CW, Xu A. *Akkermansia muciniphila* protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in *Apoe*<sup>-/-</sup> Mice. *Circulation* 2016;133:2434–46.
- [50] Wang H-B, Wang P-Y, Wang X, Wan Y-L, Liu Y-C. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription. *Dig Dis Sci* 2012;57:3126–35.
- [51] Zimmerman MA, Singh N, Martin PM, Thangaraju M, Ganapathy V, Waller JL, Shi H, Robertson KD, Munn DH, Liu K. Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. *Am J Physiol Gastrointest Liver Physiol* 2012;302:G1405–15.
- [52] De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchamp A, Bäckhed F, Mithieux G. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. *Cell* 2014;156:84–96.
- [53] Freeland KR, Wolever TMS. Acute effects of intravenous and rectal acetate on glucagon-like peptide-1, peptide YY, ghrelin, adiponectin and tumour necrosis factor- $\alpha$ . *Br J Nutr* 2010;103:460–6.
- [54] Wahlström A, Sayin SI, Marschall H-U, Bäckhed F. Intestinal Crosstalk between Bile acids and microbiota and its impact on host metabolism. *Cell Metab* 2016;24(1):41–50.
- [55] Quigley EM, Stanton C, Murphy EF. The gut microbiota and the liver. Pathophysiological and clinical implications. *J Hepatol* 2013;58:1020–7. <https://doi.org/10.1016/j.jhep.2012.11.023>. PMID:23183530.
- [56] Bajaj J. The role of microbiota in hepatic encephalopathy. *Gut Microbe* 2014;5:397–403. <https://doi.org/10.4161/gmic.28684>.
- [57] Zhang Z, Zhai H, Geng J, Yu R, Ren Y, Fan H, et al. Large-scale survey of gut microbiota associated with MHE via 16S rRNA-based pyrosequencing. *Am J Gastroenterol* 2013;108:1601–11. <https://doi.org/10.1038/ajg.2013.221>. PMID: 23877352.
- [58] Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. *Hepatology* 2011;54:562–72. <https://doi.org/10.1002/hep.24423>. PMID:21574172.
- [59] Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. *Am J Physiol Gastrointest Liver Physiol* 2012;302:G168–75. <https://doi.org/10.1152/ajpgi.00190.2011>. PMID:21940902.
- [60] Chou H, Chien WH, Wu LH, Cheng CH, Chung CH, Horng JW, et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. *Proc Natl Acad Sci USA* 2015;112:2175–80.
- [61] Ren YD, Ye ZS, Yang LZ, Jin LX, Wei WJ, Deng YY, et al. Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy. *Hepatology* 2017;65:1765–8.
- [62] Afecto E, Ponte A, Fernandez S, Silva J, Gomes C, Correia J, et al. Fecal microbiota transplantation in hepatic encephalopathy: a review of the current evidence and future perspectives. *Acta Gastroenterol Belg* 2021;84:87–90.
- [63] Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox JJ, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. *Hepatology* 2017;66:1727–38.
- [64] Bajaj J, Salzman NH, Acharya C, Sterling RK, White MB, Gavis EA, et al. Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase I, randomized, placebo-controlled trial. *J Hepatol* 2019;70:1690–703.
- [65] Palmela C, Peerani F, Castaneda D, Torres J, Itzkowitz S. Inflammatory bowel disease and primary sclerosing cholangitis: a review of the phenotype and associated specific features. *Gut and Liver* 2018;12:17–29.
- [66] O'Hara S, Karlsen T, LaRusso N. Cholangiocytes and the environment in primary sclerosing cholangitis: where is the link? *Gut* 2017;66:1873–7.
- [67] Kummen M, Holm K, Anmarkrud J, Nygard S, Vesterhus M, Hoivik M, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. *Gut* 2016;1–9.
- [68] Quraishi M, Sergeant M, Kay G, Iqbal T, Chan J, Constantinidou C, et al. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. *Gut* 2017;66:386–8.
- [69] Kummen M, Holm K, Anmarkrud J, Nygard S, Vesterhus M, Hoivik M, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. *Gut* 2017;66:611–9.
- [70] Hackam DJ, Good M, Sodhi CP. Mechanisms of gut barrier failure in the pathogenesis of necrotizing enterocolitis: toll-like receptors throw the switch. *Semin Pediatr Surg* 2013;22:76–82.
- [71] Warner BB, Deych E, Zhou Y, Hall-Moore C, Weinstock GM, Sodergren E, Shaikh N, Hoffmann JA, Linneman LA, Hamvas A, et al. Gut bacteria dysbiosis and necrotizing enterocolitis in very low birthweight infants: a prospective case-control study. *Lancet* 2016;387:1928–46.
- [72] Cassir N, Simeoni U, La Scola B. Gut microbiota and the pathogenesis of necrotizing enterocolitis in preterm neonates. *Future Microbiol* 2016;11:273–92.
- [73] Wang Q, Dong J, Zhu Y. Probiotic supplement reduces risk of necrotizing enterocolitis and mortality in preterm very low-birth-weight infants: an updated meta-analysis of 20 randomized, controlled trials. *J Pediatr Surg* 2012;47:241–8.
- [74] Beghetti I, Panizza D, Lenzi J, Gori D, Martini S, Corvaglia L, Aceti A. Probiotics for preventing necrotizing enterocolitis in preterm infants: a network meta-analysis. *Nutrients* 2021;13:192.
- [75] Braga TD, Da Silva GAP, De Lira PIC, Lima MDC. Efficacy of *Bifidobacterium breve* and *Lactobacillus casei* oral supplementation on necrotizing enterocolitis in very-low-birth-weight preterm infants: a double-blind, randomized, controlled trial. *Am J Clin Nutr* 2010;93:81–6.
- [76] Lin H-C, Hsu C-H, Chen H-L, Chung M-Y, Hsu J-F, Lien R-I, Tsao L-Y, Chen C-H, Su B-H. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. *Pediatrics* 2008;122:693–700.